- Home
- ABVC vs SILO Comparison
ABVC vs SILO Comparison
Compare ABVC & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | SILO |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 5.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABVC | SILO |
|---|---|---|
| Price | $2.08 | $0.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 84.1K | ★ 174.4K |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $797,916.00 | $72,102.00 |
| Revenue This Year | $735.18 | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 56.52 | N/A |
| 52 Week Low | $0.40 | $0.33 |
| 52 Week High | $5.48 | $3.37 |
Technical Indicators
Market Signals| Indicator | ABVC | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 34.00 |
| Support Level | $2.25 | $0.37 |
| Resistance Level | $2.53 | $0.43 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 20.35 | 2.15 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.